- Published on
KembaraXtra- Medicine – Alopecia
Alopecia refers to involuntary hair loss, most commonly affecting the scalp but potentially involving any hair-bearing area of the body. Alopecia is broadly classified into nonscarring (noncicatricial) and scarring (cicatricial) forms. Nonscarring alopecia is characterized by hair loss without permanent follicular destruction, scarring, or skin atrophy, whereas scarring alopecia results in irreversible hair loss due to follicular damage accompanied by inflammation, fibrosis, and loss of follicular openings.
Among nonscarring alopecias, alopecia areata is an autoimmune condition causing patchy hair loss on the scalp, eyebrows, eyelashes, or beard area, and may progress to alopecia totalis (complete scalp hair loss) or alopecia universalis (complete loss of body hair). Androgenetic alopecia (AGA) is the most common form of hair loss and results from genetically determined follicular sensitivity to androgens. In men, it presents as bitemporal recession, frontal thinning, and vertex balding (male pattern hair loss), while in women it manifests as diffuse central scalp thinning with preservation of the frontal hairline (female pattern hair loss). Women may initially notice increased shedding and reduced ponytail volume years before visible thinning develops.
The epidemiology of alopecia varies by etiology. Alopecia areata affects approximately 1% of the U.S. population by age 50 and occurs equally in both sexes. Androgenetic alopecia affects up to 50% of Caucasian men by age 50, with lower prevalence and later onset in Asian and African-American men. By age 70, approximately 40% of women are affected, particularly after menopause. Genetic factors play a significant role, especially in androgenetic alopecia, which is polygenic with variable penetrance, while certain scarring alopecias are more common in individuals with coarse or tightly curled hair.
The causes of alopecia are diverse and include autoimmune disorders, hormonal changes, infections, medications, nutritional deficiencies, physical or psychological stress, and trauma. Nonscarring alopecia may result from altered hair cycling (as in telogen effluvium or anagen effluvium), follicular miniaturization (as in androgenetic alopecia), hair shaft damage (from traction, trichotillomania, or cosmetic overprocessing), or immune-mediated follicular attack (as in alopecia areata). Scarring alopecia may be caused by inflammatory or autoimmune diseases such as lichen planopilaris or discoid lupus erythematosus, infections like severe tinea capitis with kerion formation, neoplasms, or congenital conditions.
Clinical evaluation begins with a thorough history, focusing on the onset, duration, and pattern of hair loss; recent stressors or illnesses; medication use; nutritional status; hair care practices; family history; and associated systemic or dermatologic symptoms. Physical examination assesses the distribution and extent of hair loss, presence of inflammation or scarring, hair shaft abnormalities, and associated findings such as virilization in women or nail changes in alopecia areata. Characteristic findings include exclamation-point hairs in alopecia areata, broken hairs of varying lengths in traumatic alopecia, and shiny atrophic skin with loss of follicular openings in scarring alopecia.
Diagnostic evaluation may include a hair pull test, where removal of six or more hairs from a gentle pull suggests active shedding, most commonly seen in telogen effluvium. Scalp biopsy is essential when scarring alopecia is suspected and should be performed with both vertical and horizontal sections for optimal histopathologic assessment. A trichogram may help quantify the proportion of anagen versus telogen hairs. Laboratory testing is guided by clinical suspicion and may include complete blood count, iron studies, thyroid function tests, autoimmune markers, and hormonal evaluation in women with signs of hyperandrogenism.
The differential diagnosis of nonscarring alopecia includes telogen effluvium, characterized by diffuse shedding following physiologic or psychological stress; androgenetic alopecia, with its characteristic patterned thinning; alopecia areata, presenting with well-demarcated patches of hair loss and autoimmune features; tinea capitis, especially in children; and traumatic alopecia, including traction alopecia and trichotillomania. Scarring alopecias include conditions such as lichen planopilaris, discoid lupus erythematosus, and inflammatory tinea capitis with kerion formation, all of which may lead to permanent hair loss if untreated.
Treatment depends on the underlying cause. Telogen effluvium is typically self-limited, with hair regrowth occurring within months once the inciting factor is removed. Androgenetic alopecia is managed with topical minoxidil in both sexes and oral finasteride in men; discontinuation of therapy results in recurrence of hair loss. Additional options include antiandrogens in selected women, hair transplantation, cosmetic camouflage, and low-level light therapy. Alopecia areata may resolve spontaneously, but treatments include topical, intralesional, or systemic corticosteroids, topical immunotherapy, and newer agents such as oral JAK inhibitors, which are now approved for severe disease in adults. Tinea capitis requires systemic antifungal therapy, and inflammatory kerion may necessitate adjunctive corticosteroids. Traction alopecia improves with elimination of the offending hairstyle or practice, while scarring alopecias focus on early inflammation control to prevent further permanent loss.
Patients with suspected scarring alopecia, treatment-resistant disease, or diagnostic uncertainty should be referred to dermatology. Education and counseling are essential, as hair loss can have a profound psychological impact. For patients with alopecia areata, support organizations and patient education resources can provide valuable guidance and reassurance.
- Published on
KembaraXtra- Medicine – Primary Aldosteronism (Hyperaldosteronism)
Primary aldosteronism is a group of disorders characterized by autonomous and excessive secretion of aldosterone, leading to renal sodium retention, suppression of plasma renin, and secondary hypertension. The condition classically presents with hypertension, hypokalemia, and metabolic alkalosis, although many patients may be normokalemic. Because aldosterone excess directly affects cardiovascular and renal systems, primary aldosteronism is now recognized as a common and clinically important cause of secondary hypertension.
Epidemiologic studies show that primary aldosteronism is far more prevalent than previously believed, particularly among patients with resistant hypertension. Current estimates suggest it may be present in 17% to nearly 27% of patients with resistant hypertension, with prevalence increasing as the severity of hypertension worsens. Familial forms of hyperaldosteronism are uncommon but should be suspected in patients with early-onset hypertension (before age 21), a family history of primary aldosteronism, or a family history of stroke before age 40.
The most common causes of primary aldosteronism include bilateral idiopathic adrenal hyperplasia, which accounts for approximately 60% to 70% of cases, and unilateral aldosterone-producing adenomas (Conn syndrome), which account for about 30% to 40%. Less common causes include unilateral adrenal hyperplasia, familial hyperaldosteronism, adrenal carcinoma, and ectopic aldosterone production. The underlying cause is important because it directly determines treatment strategy.
Clinically, many patients are asymptomatic aside from hypertension. When present, manifestations may include resistant hypertension, spontaneous or diuretic-induced hypokalemia, muscle weakness, fatigue, or a history of early cardiovascular events. A family history of early hypertension or stroke should heighten suspicion. Because symptoms may be subtle or absent, a high index of suspicion is required, particularly in patients whose blood pressure remains uncontrolled despite multiple antihypertensive agents.
Diagnosis begins with recognition of the biochemical pattern of suppressed plasma renin activity and elevated serum aldosterone levels, typically with aldosterone concentrations exceeding 15 ng/dL. Screening is recommended in patients with resistant hypertension, early-onset hypertension, hypokalemia, adrenal incidentalomas, sleep apnea, or a strong family history of hypertension or stroke. The aldosterone-to-renin ratio (ARR) is commonly used as an initial screening test, although its sensitivity is limited. When results are inconclusive, 24-hour urinary aldosterone excretion under aldosterone-suppressing conditions may be required for confirmation.
Routine laboratory findings are not diagnostic but may support the diagnosis, including hypokalemia, metabolic alkalosis, and occasionally mild hypernatremia. Once biochemical confirmation is obtained, imaging is performed to determine whether aldosterone excess is unilateral or bilateral. Adrenal CT scanning is the preferred imaging modality, as adrenal adenomas are typically lipid-rich and well visualized on CT. MRI may be used as an alternative. However, imaging alone cannot reliably distinguish unilateral from bilateral disease.
To definitively differentiate unilateral from bilateral aldosterone secretion, adrenal vein sampling (AVS) is recommended in most patients who are surgical candidates. This distinction is critical, as unilateral disease is best treated surgically, whereas bilateral disease requires medical therapy. AVS should be performed by experienced interventional radiologists to ensure accurate results.
Management includes both nonpharmacologic and pharmacologic strategies. Lifestyle measures such as regular blood pressure monitoring, a low-sodium diet, tobacco avoidance, weight management, and regular exercise are recommended for all patients. Acute management focuses on controlling hypertension and correcting hypokalemia, typically using mineralocorticoid receptor antagonists such as spironolactone or eplerenone, or potassium-sparing agents like amiloride.
Long-term medical therapy is the mainstay for patients with bilateral adrenal hyperplasia. Spironolactone is usually initiated at a low dose and titrated upward every two weeks to achieve a normal serum potassium level without supplementation. Eplerenone is an effective alternative with fewer antiandrogenic side effects, such as gynecomastia or menstrual irregularities. Amiloride may be used in patients who cannot tolerate mineralocorticoid receptor antagonists.
For patients with unilateral aldosterone-producing adenomas or unilateral adrenal hyperplasia, laparoscopic adrenalectomy is the treatment of choice. Surgical treatment typically resolves hypokalemia and improves blood pressure control, although hypertension persists in 40% to 65% of patients postoperatively. Complete resolution of hypertension is more likely in younger patients, those with a shorter duration of hypertension, fewer preoperative antihypertensive medications, no family history of hypertension, and higher aldosterone-to-renin ratios.
Overall, treatment of primary aldosteronism—whether surgical or medical—results in meaningful improvements in blood pressure control, potassium balance, and cardiovascular and renal outcomes. Untreated disease is associated with higher risks of stroke, myocardial infarction, atrial fibrillation, left ventricular hypertrophy, and decline in kidney function compared with essential hypertension. These risks are significantly reduced with appropriate therapy, and in many cases, surgical treatment lowers cardiovascular risk to below that of matched patients with essential hypertension.
- Published on
KembaraXtra- Medicine – Allergic Rhinitis
Allergic rhinitis (AR) is an immunoglobulin E (IgE)–mediated hypersensitivity reaction to inhaled environmental allergens that leads to inflammation of the nasal mucosa. This inflammatory process is driven primarily by type 2 helper T (Th2) cells and results in the characteristic symptoms of sneezing, rhinorrhea, nasal pruritus, and nasal congestion. Allergic rhinitis may be seasonal, triggered by pollens, or perennial, caused by year-round allergens such as dust mites, molds, and animal dander.
Allergic rhinitis is highly prevalent, affecting 10% to 30% of the U.S. population and up to 40% of children, with substantial impact on quality of life, school performance, and workplace productivity. The mean age of onset is between 8 and 12 years, and approximately 80% of cases develop before age 20. Sensitization to aeroallergens is uncommon before the age of one year. Among patients presenting to primary care with nasal complaints, allergic rhinitis accounts for 30% to 60% of cases.
Clinically, allergic rhinitis is distinguished from nonallergic rhinitis by the presence of sneezing, nasal itching, and ocular pruritus. Both allergic and nonallergic rhinitis may cause nasal congestion, postnasal drip, and cough. Additional symptoms include fatigue, irritability, reduced sense of smell, and a sensation of ear fullness. Physical examination often reveals pale or violaceous, edematous nasal turbinates caused by venous engorgement, a feature that helps distinguish allergic rhinitis from viral rhinitis, which typically presents with erythematous mucosa. Other findings may include clear nasal discharge, posterior pharyngeal drainage, conjunctival injection, throat erythema, and occasionally nasal polyps.
The most common triggers of allergic rhinitis include pollens (trees in spring, grasses in summer, and weeds in fall), as well as dust mites, mold spores, and animal allergens. Nonallergic irritants such as smoke, strong odors, and pollution may exacerbate symptoms in both allergic and nonallergic rhinitis but do not represent the primary mechanism of disease.
Diagnosis is largely clinical, based on history and physical examination. Many patients do not require formal diagnostic testing if symptoms and triggers are typical. A seasonal pattern of symptoms can help identify the likely allergen source, whereas year-round symptoms suggest perennial allergens. Allergy testing, either by skin testing or serum-specific IgE testing, may be useful in patients with persistent symptoms despite standard therapy, those considering allergen immunotherapy, or when precise identification of allergens is necessary for avoidance strategies.
Management begins with nonpharmacologic measures, including allergen avoidance when feasible. Strategies include dust mite control with mattress and pillow encasements, removal of carpeting and allergen-collecting items from the bedroom, use of HEPA air filtration, and limiting exposure to pets in sensitized individuals. Nasal saline sprays or irrigations are effective adjunctive therapies that reduce nasal dryness, congestion, and allergen load.
For pharmacologic treatment, intranasal corticosteroids are the preferred first-line therapy for most patients with allergic rhinitis. These agents effectively reduce nasal inflammation and improve all major symptoms, although maximal benefit may take at least one week of regular use. In patients with moderate to severe disease, combination therapy with an intranasal corticosteroid and an intranasal antihistamine provides greater symptom control than either agent alone. Oral second-generation antihistamines may be helpful for persistent ocular symptoms but offer little additional benefit when combined with intranasal corticosteroids for nasal symptoms. Montelukast should be reserved for patients who cannot tolerate or do not respond to first-line therapies, and intranasal ipratropium may be considered when rhinorrhea is the predominant complaint.
For patients with persistent or severe symptoms despite optimal medical therapy, allergen immunotherapy may be considered. Both subcutaneous and sublingual immunotherapy can significantly reduce symptoms and medication use, with approximately 80% of patients reporting improvement. Immunotherapy is contraindicated in patients with uncontrolled asthma, a history of severe reactions to immunotherapy, and—specifically for sublingual therapy—those with eosinophilic esophagitis.
Overall, the prognosis of allergic rhinitis is excellent. Most patients achieve good symptom control with appropriate avoidance strategies and medical therapy. Referral to an allergist or otolaryngologist is appropriate for patients with moderate to severe disease, those unresponsive to treatment, or individuals interested in immunotherapy.
- Published on
KembaraXtra- Medicine – Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AATD) is an inherited genetic disorder caused by deficiency or dysfunction of the protease inhibitor alpha-1-antitrypsin (AAT). The condition most commonly results from homozygous carriage of the SERPINA1 Z allele (PI*ZZ genotype). This mutation leads to production of an abnormal AAT protein (Z-AAT) that accumulates within hepatocytes while circulating levels of functional AAT are markedly reduced. The resulting imbalance predisposes affected individuals to early-onset pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and progressive liver disease, including cirrhosis and hepatocellular carcinoma.
Alpha-1-antitrypsin deficiency is underrecognized but accounts for approximately 1% to 5% of COPD cases in the United States, with an estimated prevalence of 1 in 2000 to 5000 individuals. The disorder is inherited in an autosomal codominant fashion. The normal M allele is present in about 95% of the population, while the deficient Z allele occurs in 1% to 2% and the S allele in 2% to 3%. Severe deficiency most often occurs in individuals with the ZZ genotype, while those with SZ or MZ genotypes may have partial deficiency, with increased risk of lung disease—particularly in smokers. Approximately 1 in 10 individuals of European descent carries at least one abnormal allele.
Clinical manifestations vary depending on genotype and environmental exposures. The lungs are most commonly affected, with patients developing early-onset, lower-lobe–predominant panlobular emphysema, often before age 45 and sometimes in the absence of smoking. Symptoms resemble typical COPD and include progressive dyspnea, chronic cough, and sputum production. Bronchiectasis may also be present. Smoking significantly accelerates lung damage and worsens prognosis. Liver involvement may present as neonatal cholestasis, chronic hepatitis, cirrhosis, or hepatocellular carcinoma in both children and adults. A rare dermatologic manifestation is panniculitis, characterized by painful, inflammatory subcutaneous nodules caused by unopposed proteolysis in the skin.
The pathophysiology of AATD involves loss of antiprotease protection in the lungs and toxic accumulation of mutant AAT protein in hepatocytes. In the lungs, reduced AAT levels fail to adequately inhibit neutrophil elastase, leading to destruction of alveolar elastin and development of emphysema. In the liver, disease results not from deficiency but from intracellular retention of misfolded Z-AAT, which triggers hepatocellular injury, inflammation, and fibrosis. Not all individuals with AAT deficiency develop clinical disease, but smoking is the strongest modifiable risk factor for lung involvement.
Diagnosis should be suspected in patients with early-onset COPD, emphysema without typical risk factors, or basilar-predominant emphysema on imaging. Unexplained liver disease, panniculitis, bronchiectasis, poorly responsive asthma, or c-ANCA–associated vasculitis should also prompt evaluation. Initial testing includes measurement of serum alpha-1-antitrypsin levels, followed by genotyping to identify specific alleles. Pulmonary function testing typically shows airflow obstruction consistent with COPD. Imaging with chest radiography or high-resolution computed tomography often demonstrates lower-lobe–predominant emphysema and may reveal bronchiectasis.
Management begins with nonpharmacologic interventions, most importantly complete avoidance of smoking, which dramatically reduces the risk and progression of lung disease. Patients should also avoid occupational and environmental exposures that damage the lungs and receive routine vaccinations, including influenza, pneumococcal, pertussis, and SARS-CoV-2 vaccines. Acute COPD exacerbations are treated similarly to those in patients without AATD.
For chronic management, the therapeutic goal is to raise serum AAT levels above the protective threshold of approximately 50 mg/dL. Currently, the only FDA-approved disease-specific therapy is intravenous alpha-1-antitrypsin augmentation therapy, which uses pooled human AAT to slow progression of emphysema. This treatment requires lifelong administration, is costly, and does not reverse established lung damage nor improve liver disease. Patients with end-stage lung or liver disease may be candidates for organ transplantation, which can be life-saving and curative for the affected organ.
Prognosis depends on genotype, degree of deficiency, and environmental factors. Among patients with severe AATD, respiratory failure is the leading cause of death, followed by cirrhosis and liver-related complications. Early diagnosis, smoking cessation, and appropriate specialty care significantly improve outcomes. Referral to clinicians experienced in managing AATD is recommended, including pulmonology, hepatology, and transplant centers when indicated.
Alpha-1-antitrypsin deficiency remains substantially underdiagnosed, and expert guidelines recommend testing all patients with COPD, emphysema, irreversible asthma, unexplained liver disease, bronchiectasis, or panniculitis, as well as first-degree relatives of affected individuals. Early recognition allows for risk reduction, appropriate monitoring, and timely intervention to prevent irreversible organ damage.
- Published on
KembaraXtra-Medicine – Anal Cancer
Anal cancer refers to malignant transformation of the mucosa within the anal canal and may be squamous, neuroendocrine, or adenocarcinoma in subtype. It is also known as anal carcinoma, cancer of the anal canal, or malignant neoplasm of anus. The ICD-10CM code listed is C21.1 (Malignant neoplasm of anal canal).
Anal cancer is uncommon, occurring at a rate of 1–2 new cases per 100,000 population, with a median age of 63 years; in HIV-infected patients, the median age is <50 years. in the united states, 2022 estimates projected 9440 new cases and 1670 deaths. worldwide, 2020 (globocan) 50,865 19,293 deaths from anal cancer. incidence has increased 2%–3% annually over last 3 decades u.s., including young black men older women. there also been an increase locally advanced (node-positive) distant-disease cases, along with mortality elderly patients.< />pan>
The rise in incidence has been noted alongside the HIV epidemic and increased rates of sexually transmitted diseases. Risk factors include HIV infection (and unlike other HIV-associated malignancies, anal cancer incidence has not decreased in the era of highly active antiretroviral therapy), human papillomavirus (HPV) infection, cigarette smoking, and sexual practice risks such as men who have sex with men (MSM), women with >10 partners, and a history of anal intercourse. Additional risks include prior sexually transmitted diseases, genital warts, prior cervical cancer, and chronic immunosuppression.
Clinical presentation is often related to tumor size and degree of infiltration. Anorectal bleeding is the most common symptom, and patients may also report anorectal pain and fullness, as well as bowel habit changes including thin-caliber stools and a sense of incomplete evacuation. However, 20%–25% of patients may be asymptomatic. Local examination may reveal skin lesions, plaques, tumors, and a background of warts. Digital rectal examination assesses sphincter function, tumor location and size, tumor extent, and possible involvement of adjacent organs (e.g., vagina, prostate, rectum). At diagnosis, most cases are localized (85%), while the remainder are advanced or metastatic; inguinal adenopathy may be present in advanced disease.
Anal cancer development is strongly linked to anogenital HPV infection, especially HPV-16 and HPV-18, which account for most cases. Most infected individuals remain asymptomatic, and only some develop dysplasia over time. HPV proteins E6 and E7 promote oncogenesis by preventing apoptosis, causing cell-cycle arrest, and contributing to genomic instability. Chronic immunosuppression (e.g., from autoimmune therapy or organ transplantation) increases genital warts and persistence of HPV infection, promoting anal intraepithelial neoplasia (AIN) and eventual cancer. In HIV infection, low CD4 counts are a risk factor for development and progression of AIN.
The differential diagnosis includes anal fissures and fistulas, anal ulcers, anorectal abscess, chancroid, genital warts, and hemorrhoids.
Workup begins with careful local assessment: local examination followed by anoscopy/proctoscopy and colonoscopy to evaluate tumor extent. Imaging includes CT scans of the chest, abdomen, and pelvis to assess nodal and distant disease; pelvic MRI for tumor detail, sphincter involvement, and mesorectal nodal evaluation; and PET scans to detect nodal involvement and to help monitor response to therapy. Biopsy of the anal lesion is required to confirm diagnosis and cancer type, and inguinal nodal biopsy may be necessary to determine metastatic involvement. Recommended diagnostic evaluation includes digital rectal examination with tumor characterization, inguinal lymph node examination with biopsy or fine-needle aspiration if suspicious, anoscopy with biopsy, and in females a gynecologic examination including cervical cancer screening. Additional evaluation includes diagnostic PET-CT of chest/abdomen/pelvis (or pelvic MRI), CBC with serum chemistries, and HIV testing with CD4 levels in patients with risk factors. Laboratory tests include CBC, a complete metabolic panel, and HIV testing.
Staging uses TNM descriptors. T categories include Tx (cannot be assessed), T0 (no evidence), Tis (carcinoma in situ--Bowen disease/HSIL/AIN II-III), T1 (≤2 cm), T2 (>2 cm to ≤5 cm), T3 (>5 cm), and T4 (any size invading adjacent organ[s]); invasion of the rectal wall, perirectal skin, subcutaneous tissue, or sphincter muscles is not classified as T4. N categories include Nx (cannot be assessed), N0 (no regional metastasis), N1 (perirectal nodes), N2 (unilateral internal iliac and/or inguinal nodes), and N3 (perirectal and inguinal nodes and/or bilateral internal iliac and/or inguinal nodes). M categories are M0 (no distant metastasis) and M1 (distant metastasis). Stage groupings are: Stage 0 (Tis N0 M0), Stage I (T1 N0 M0), Stage II (T2–T3 N0 M0), Stage IIIA (T1–T3 N1 M0 or T4 N0 M0), Stage IIIB (T4 N1 M0 or any T with N2/N3 M0), and Stage IV (any T, any N, M1).
For most anal cancers, the mainstay of therapy is nonsurgical, using radiotherapy concurrent with systemic chemotherapy. Early small tumors (T1N0)—especially on the anal margin—may be treated with local surgical resection with wide margins. In some patients, a temporary colostomy may be needed to facilitate chemoradiotherapy. Abdominoperineal resection (APR) is generally reserved as salvage for persistent disease after definitive chemoradiotherapy or for locoregional recurrence.
Historically, APR achieved surgical cures in 25%–75%, but had up to a 35% locoregional relapse rate, especially with nodal involvement. Current standard care is mitomycin plus infusional 5-fluorouracil given concurrently with pelvic radiotherapy over about 5 weeks (CRT). If response is incomplete and biopsies remain positive, options include a radiotherapy boost or salvage APR. Combined-modality CRT is superior to radiotherapy alone and improves locoregional control, progression-free survival, overall survival, and colostomy-free survival. Major toxicities include myelosuppression, infections, dermatologic toxicity, and GI toxicity. Current clinical trials are studying radiotherapy de-escalation within CRT to reduce toxicity and improve tolerability and compliance. Locoregional recurrence occurs in about 10%–30%, and 5-year survival after salvage APR is about 40%–60%.
For distant metastatic or nonsurgical advanced disease, combination chemotherapy is preferred. Triplet regimens such as docetaxel/cisplatin/5-fluorouracil (DCF) may be used in fit patients, with >80% response rates and ~25% 5-year survival. Doublets such as CF (cisplatin/5-FU) or CP (carboplatin/paclitaxel) have response rates around 60% and median overall survival ~2 years; due to favorable toxicity, CP is preferred. In chemotherapy-refractory advanced disease, options include immune checkpoint inhibitors (nivolumab, pembrolizumab, avelumab, atezolizumab), and cetuximab (anti-EGFR) may be used palliatively.
Long-term care may include colostomy care and attention to nutritional requirements. Ongoing regular follow-up and examination are recommended to detect locoregional or distant recurrence. Referral is typically made to surgical oncology, radiation oncology, and medical oncology.
No formal screening guideline exists, but high-risk individuals (e.g., chronic immunosuppression, HIV, MSM) should be considered for routine local exam with anoscopy every 4–6 months plus annual anal cytology. Prevention is expected to be influenced by HPV vaccination. Gardasil 9 protects against nine HPV subtypes. Recommendations include vaccination for all children ages 11–12, girls/women ages 13–26, boys/men ages 13–21, and high-risk men ages 22–26, with an expanded indication allowing ages 27–45 to receive catch-up vaccination. In a randomized trial of 4459 participants with biopsy-proven HSIL, active treatment (office-based ablation, ablation/excision under anesthesia, or topical fluorouracil or imiquimod) continued until HSIL resolved, with high-resolution anoscopy at least every 6 months and biopsies per protocol. Over a median follow-up of 25.8 months, progression to anal cancer was 57% lower in the treatment group than in the active-monitoring group.
- Published on
KembaraXtra-Medicine – Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal degenerative neuromuscular condition of undetermined etiology that affects the corticospinal tracts and anterior horn cells, resulting in dysfunction of both upper motor neurons (UMNs) and lower motor neurons (LMNs). Synonyms include Lou Gehrig disease, ALS, and motor neuron disease. The ICD-10CM code is G12.21 (Amyotrophic lateral sclerosis).
ALS incidence is about two new cases per 100,000 persons per year. Onset is usually between 50 and 70 years, and the male-to-female ratio is 1.8:1. The estimated prevalence is 5.2 per 100,000 population.
Clinical presentation typically includes a combination of LMN signs—weakness, hypotonia, muscle wasting, fasciculations, and hyporeflexia or areflexia—and UMN signs—loss of fine motor dexterity, spasticity, extensor plantar responses, hyperreflexia, and clonus. Extraocular movements, sensation, and bowel and bladder function are typically preserved. Patients may develop dysarthria, dysphagia, pseudobulbar affect, and frontal lobe dysfunction. Respiratory insufficiency progresses to respiratory failure and death, typically late in the disease. Concomitant frontotemporal dementia occurs in about 15%, and executive dysfunction occurs in another 50%. Pseudobulbar affect (inappropriate crying or laughing not triggered by typical emotional cues) is common and treatable.
ALS commonly manifests in one of three onset patterns. Limb onset accounts for 75%–80% of cases and presents with painless muscle weakness, clumsiness (dropping things, stumbling, falling), impaired fine motor skills (e.g., writing), limb stiffness, gait disturbances, and wristdrop or footdrop. Bulbar onset accounts for 20%–25% and presents with dysarthria or voice change, pseudobulbar affect, dysphagia and/or weight loss, drooling, and choking during swallowing. Respiratory onset occurs in <3% and presents with dyspnea on exertion or at rest, orthopnea, daytime sleepiness, difficulty sleeping, other symptoms of respiratory compromise. als makes up about 90% adult-onset motor neuron diseases; disease presentations include progressive muscular atrophy, primary lateral sclerosis, bulbar palsy, pseudobulbar als-parkinsonism-dementia complex.< />pan>
Regarding etiology and classification, 90% of cases are sporadic and 10% are familial. Known genetic mutations include C9orf72 hexanucleotide repeat expansion (responsible for ~40% of familial ALS among those of European origin and nearly 10% of sporadic ALS, and virtually all ALS cases associated with frontotemporal dementia), SOD1 (copper-zinc superoxide dismutase) mutations (~12% of familial cases), TAR DNA-binding protein mutations (~4% of familial cases), and FUS (~4% of familial cases, rarely associated with frontotemporal dementia), among many others. Risk is increased in Whites, non-Hispanics, age >60 years, family history of ALS, and prior exposure to heavy metals, pesticides, or BMAA. A practical classification includes sporadic/acquired ALS variants (classic spinal-onset, Mills hemiplegic variant, pseudoneuritic, flail-arm, monomelic, UMN onset, LMN onset, bulbar onset, dyspnea onset, progressive muscular atrophy, primary lateral sclerosis, progressive bulbar palsy, Western Pacific ALS) and multiple familial ALS subtypes (ALS1 through ALS25 and additional rare-mutation forms). An FTD-ALS overlap is also recognized (e.g., ALS-FTD associated with C9orf72; and FTD with some ALS features associated with tau and progranulin genes on chromosome 17).
The differential diagnosis includes multifocal motor neuropathy with conduction block; cervical spondylotic myelopathy with polyradiculopathy; spinal stenosis with lumbosacral nerve root compression; chronic inflammatory demyelinating polyneuropathy with CNS lesions; syringomyelia; syringobulbia; foramen magnum tumor; meningeal carcinomatosis; spinal muscular atrophy; polyglucosan body disease; bulbospinal muscular atrophy (Kennedy disease); monomelic amyotrophy; Lyme disease; and ALS-like syndromes reported with lead intoxication, HIV, hyperparathyroidism, hyperthyroidism, lymphoma, and vitamin B12 deficiency.
Diagnosis is based on clinical findings, electromyography results, and exclusion of alternative causes. Workup includes MRI of brain and spine to exclude mimics; electromyography and nerve conduction studies following Revised El Escorial criteria; assessment of respiratory function (forced vital capacity [FVC], negative inspiratory force); assessment of swallowing and nutritional status; and neuropsychologic testing if executive dysfunction or FTD is a concern. The Revised El Escorial criteria require evidence of LMN degeneration (clinical, electrophysiologic, or neuropathologic), evidence of UMN degeneration (clinical), and progressive spread of symptoms/signs within or between regions, together with absence of electrophysiologic/pathologic evidence of another disease explaining UMN/LMN degeneration and absence of neuroimaging evidence of another explanatory disease process. Levels of certainty include Definite ALS (UMN and LMN signs in three regions), Probable ALS (UMN and LMN signs in two regions with UMN signs rostral to LMN signs), Probable ALS—Laboratory Supported (UMN signs in one or more regions with LMN signs by EMG in at least two regions), and Possible ALS (UMN and LMN signs in one region together, or UMN signs in two or more regions, or UMN and LMN signs in two regions without UMN signs rostral to LMN signs).
Laboratory tests that may be considered include vitamin B12, thyroid function, parathyroid hormone, and HIV, plus serum protein electrophoresis with immunofixation. In pure LMN syndromes, consider DNA studies for spinal muscular atrophy, bulbospinal atrophy (Kennedy disease), and hexosaminidase levels (late-onset Tay-Sachs). A 24-hour urine heavy metal screen may be done if indicated. In familial ALS, genetic studies should be performed with appropriate genetic counseling. Imaging is guided by clinical scenario; MRI brain and spinal cord help exclude structural mimics, and a modified barium swallow evaluates aspiration risk.
Treatment includes symptomatic management plus disease-modifying therapy that slows progression in some patients. Symptomatic treatment options span multiple domains: fatigue (pyridostigmine bromide, antidepressants, methylphenidate, amantadine, modafinil; energy conservation, work modification, sleep study with BiPAP if abnormal), spasticity (baclofen, tizanidine, dantrolene sodium, diazepam; physical therapy, range-of-motion exercises, botulinum toxin), jaw clenching (benzodiazepines, botulinum toxin into masseters), cramps (quinine sulfate, baclofen, vitamin E, clonazepam; massage, physical therapy), fasciculations (carbamazepine and reassurance), sialorrhea (hyoscyamine sulfate, diphenhydramine, scopolamine patch, glycopyrrolate, atropine, TCAs; suction machine, botulinum toxin into salivary glands, parotid radiation therapy, steam inhalation, nebulization, dark grape juice), pseudobulbar laughing/crying (TCAs, SSRIs, L-dopa/carbidopa, lithium, mirtazapine, venlafaxine, quinidine/dextromethorphan), thick phlegm (guaifenesin, nebulized N-acetylcysteine, nebulized saline, propranolol; insufflation-exsufflation, high-flow chest wall oscillation therapy, cool mist humidifier, rehydration, pineapple/papaya juice, reduced dairy/caffeine/alcohol), aspiration (cisapride and modified food consistency; in severe cases tracheostomy or modified laryngectomy with tracheal diversion), joint pains (anti-inflammatory drugs, analgesics, range-of-motion and heat), depression (TCAs; SSRIs/venlafaxine/mirtazapine/bupropion; counseling, support groups, psychiatry), insomnia (zolpidem tartrate, lorazepam, opioids, TCAs; pressure air pad/gel mattress; noninvasive ventilation where appropriate), laryngospasm (sublingual lorazepam), respiratory failure (bronchodilators, morphine sulfate; hospital bed, nocturnal noninvasive ventilator, IPPB), and constipation (increase oral fluids, Metamucil, Dulcolax suppositories, lactulose/other laxatives, exercise, “power pudding” of prune juice/prunes/applesauce/bran).
Nonpharmacologic therapy is central. Noninvasive ventilation can improve quality of life and may increase tracheostomy-free survival in patients with respiratory difficulty (orthopnea or FVC ≤50% predicted). Percutaneous endoscopic gastrostomy (PEG) can improve nutrition, stabilize weight, and ease medication administration; some studies suggest it may prolong life by 1–4 months, especially when placed before FVC falls to ≤50% predicted. Supportive services include nutrition support, speech therapy, physical and occupational therapy, suction devices for sialorrhea, cough assist devices for ineffective cough and airway clearance, and computerized assistive communication devices. Early advance-care planning discussions should address living will, resuscitation orders, preferences regarding PEG and tracheostomy, and long-term care options, and patients should be encouraged to connect with local support groups.
Disease-modifying medications do not cure ALS but can slow progression in selected patients. Riluzole (glutamate antagonist) was the first FDA-approved medication shown to extend tracheostomy-free survival; typical dosing is 50 mg every 12 hours, taken at least 1 hour before or 2 hours after meals, and it prolongs survival by about 2–3 months; ALT monitoring is recommended monthly for the first 3 months, then every 3 months until completion of the first year, and periodically thereafter. Edaravone (FDA approved 2017) slowed physical decline by 33% versus placebo in a 6-month phase III trial; it is given IV with an initial cycle of daily infusions for 14 days followed by 14 days off, then subsequent cycles of 10 infusions over 14 days followed by 14 days off; cost and insurance coverage can be limiting. Relyvrio (sodium phenylbutyrate/taurursodiol) is an FDA-approved oral fixed-dose combination (approved 2022) for adults with ALS that helps slow progression; its exact mechanism is unknown, but it targets endoplasmic reticulum and mitochondria-dependent neuronal degeneration pathways, and is thought to reduce neuronal death and dysfunction.
Chronic management includes targeted symptom control such as treating sialorrhea with glycopyrrolate or amitriptyline (and considering propranolol or metoprolol if secretions are thick), using botulinum toxin if refractory; treating spasticity with baclofen, tizanidine, or clonazepam; and treating pseudobulbar affect with amitriptyline, sertraline, or dextromethorphan/quinine.
Disposition reflects the progressive nature of ALS: there is currently no cure, mean symptom duration is 3-5 years, and about 20% of patients survive more than 5 years. Referral to a neurologist experienced in neuromuscular disease is recommended to confirm diagnosis, and multidisciplinary ALS clinics may improve survival. Gastroenterology referral for PEG placement is recommended while FVC remains >50% to reduce procedural morbidity, and pulmonology referral is appropriate for noninvasive ventilation such as BiPAP.
Pearls include the importance of patient-physician communication at diagnosis and throughout care, and the value of a multidisciplinary supportive approach to improve daily functioning and independence. Related content includes patient information resources on ALS.
- Published on
KembaraXtra-Medicine – Anaerobic Infections
Anaerobic infection is caused by bacteria that require a reduced oxygen tension for growth. Relevant ICD-10CM codes include A41.4 (Sepsis, anaerobic) and A48 (Cellulitis, anaerobic).
Anaerobic infections may occur at any site, but most are anatomically related to mucosal surfaces. They should be suspected when there is foul-smelling tissue, soft tissue gas, necrotic tissue, or abscess formation. In the head and neck, odontogenic infections from dental or soft tissue sources may progress to periapical abscesses and sometimes extend to bone. Chronic sinusitis, chronic mastoiditis, peritonsillar abscess, and chronic otitis media can involve both anaerobic and aerobic pathogens. Complications include deep neck space infections, brain abscesses, and mediastinitis. Specific head and neck examples include Ludwig angina, a bilateral infection of the sublingual and submandibular spaces causing swelling at the base of the tongue with potential airway compromise and usually involving mixed aerobic/anaerobic flora, and Lemierre syndrome, a jugular vein suppurative thrombophlebitis caused by anaerobic bacteria, classically Fusobacterium necrophorum.
In pleuropulmonary disease, infection may involve anaerobes that normally reside in the oropharynx. Aspiration is more common in people with altered mental status or seizures, and anaerobic infection is more likely in those with gingivitis or periodontitis. Manifestations include necrotizing pneumonia, empyema, and lung abscess. In intraabdominal infections, disruption of intestinal integrity can lead to anaerobic infection; bacteria may originate from colonic neoplasm, perforated appendicitis, diverticulitis, or bowel surgery, resulting in bacteremia, peritonitis, and sometimes intraabdominal abscesses. These infections are usually mixed, containing both anaerobes and aerobes. In the female genital tract, anaerobes are involved in bacterial vaginosis, salpingitis, endometritis, pelvic abscesses, and septic abortion, and these infections also tend to be mixed. Pelvic thrombophlebitis may occur when a resolving pelvic infection is accompanied by new or persistent fever.
Other anaerobic infections include skin and soft tissue infections at any site, with more commonly associated entities such as synergistic gangrene, bite wound infections, and infected decubitus ulcers. The clinical significance of anaerobes in diabetic foot infections is unclear. Anaerobic bacteremia is not common; when it occurs the source is most often intraabdominal, followed by female genital tract, pleuropulmonary, and head/neck sources. Anaerobes can also be involved in osteomyelitis, especially when associated with decubitus ulcers or vascular insufficiency, and facial bone osteomyelitis can arise from adjacent infections of teeth or sinuses.
Etiologically, anaerobic infections are most commonly endogenous, arising from bacteria that normally line mucosal surfaces. Infection results when mucosal barriers are disrupted by trauma, ischemia, surgery, or perforation, allowing organisms access to normally sterile sites, causing tissue destruction and abscess formation. Synergy between different anaerobes, or between anaerobes and aerobes, is important. Examples of anaerobic bacteria include gram-negative organisms such as Bacteroides spp., Fusobacterium, and Prevotella spp., and gram-positive organisms such as Peptostreptococcus, Clostridioides spp., Finegoldia magna, and Actinomyces spp.
The main differential diagnosis is an aerobic bacterial infection without anaerobes. Another key differential is ischemic necrosis without infection, distinguishing “dry” gangrene (noninfected necrosis) from “wet” gangrene (infected tissue with anaerobic infection).
Workup requires attention to specimen handling: samples submitted for anaerobic culture should be processed within 30 minutes, and growth may take 5–7 days. A large volume of material is more likely to yield significant growth; swabs are less efficient for transporting infected material. Blood cultures should be obtained, preferably before antibiotics are given. Laboratory findings may include elevated WBC count (extremely high counts can be seen with pseudomembranous colitis), positive stool C. difficile testing by PCR/NAAT, increased lactate levels in ischemia or perforation, and possible positive blood or wound cultures—though failure to grow anaerobes is common due to inadequate culturing techniques or fastidious organisms. Imaging may include plain films to show gas in tissues, free air from perforated viscus, or air/fluid levels within an abscess, and ultrasound/CT/MRI to identify abscesses or tissue destruction.
Treatment includes nonpharmacologic measures such as removal of necrotic tissue and drainage of abscesses, often accomplished via CT-guided percutaneous drainage. Oral antibiotic options with anaerobic activity include clindamycin, metronidazole, and chloramphenicol, with broader coverage from amoxicillin/clavulanate; penicillin VK is used for odontogenic infections. For C. difficile–associated diarrhea, oral vancomycin is now the preferred agent, while metronidazole is considered second-line; oral vancomycin is used for subsequent episodes and for pulse or taper regimens. For more serious illness, parenteral options include IV clindamycin, metronidazole, and chloramphenicol; cephalosporins with anaerobic or mixed coverage such as cefoxitin and cefotetan; extended-spectrum penicillins (e.g., piperacillin) and beta-lactam/beta-lactamase inhibitor combinations with significant anaerobic activity and varying broad-spectrum coverage, including ampicillin/sulbactam, ticarcillin/clavulanate, and piperacillin/tazobactam; and carbapenems such as imipenem, meropenem, doripenem, or ertapenem, which have extensive anaerobic activity. Actinomycosis is treated with penicillin for 6–12 months. Sulfamethoxazole-trimethoprim and fluoroquinolones are generally ineffective, though some newer quinolones such as moxifloxacin have inhibitory activity against anaerobes.
Disposition emphasizes that all necrotic debris must be removed or the infection will recur, and follow-up is critically important to ensure resolution. Referral to a surgeon is appropriate if drainage is required, and infectious disease consultation may be helpful in complicated patients or when the regimen is failing or response is slow. Resistance rates are generally low for many agents used against anaerobes (reported rates: piperacillin/tazobactam 0.5%, ampicillin/sulbactam 3%), though one study found >50% resistance of Bacteroides fragilis to clindamycin.
- Published on
KembaraXtra-Medicine – Amaurosis Fugax
Amaurosis fugax is defined as a transient loss of monocular vision caused by temporary retinal ischemia resulting from a reversible occlusion of the ophthalmic artery or its branches. The ophthalmic artery arises from the internal carotid artery, and the central retinal artery is a branch of the ophthalmic artery. This condition is classified under ICD-10CM code G45.3 and is considered an important warning sign of underlying vascular disease.
From an epidemiologic perspective, amaurosis fugax is an uncommon but clinically significant presentation of carotid artery disease in the United States. The peak incidence occurs around 55 years of age, and its recognition is critical because it often represents a form of transient ischemic attack (TIA) with potential risk for future stroke.
The clinical presentation is typically sudden in onset and lasts seconds to minutes. Patients often describe the vision loss as a shade or curtain descending over the eye, most commonly from above downward. The visual deficit may be complete or partial and can involve hemianopic or quadrantic vision loss. During the acute stage, cholesterol emboli, known as Hollenhorst plaques, may sometimes be visualized within the retinal arteries on funduscopic examination.
The etiology of amaurosis fugax is most often embolic in nature. Emboli may originate from the internal carotid artery, usually in the setting of carotid atherosclerotic stenosis, or from the heart, with atrial fibrillation being the most common cardiac source. Carotid artery emboli are typically identified as stenosis on carotid imaging such as CT angiography, MR angiography, or carotid ultrasound. Other important causes include giant cell arteritis, which produces inflammatory occlusion of retinal arteries; hyperviscosity syndromes such as sickle cell disease; hypercoagulable states; and reversible cerebral vasoconstriction syndrome.
In terms of differential diagnosis, retinal migraine must be considered, as it differs by having a gradual onset of visual symptoms over 15 to 20 minutes rather than sudden loss. Transient visual obscurations associated with papilledema also differ, as they are typically brief (1–2 seconds), may be binocular, and are related to transient increases in intracranial pressure. If vision loss persists at the time of evaluation, the differential should be expanded to include arteritic or nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and branch retinal artery occlusion.
The diagnostic workup should prioritize identifying embolic sources, while giant cell arteritis must always be considered, particularly in older adults. A careful retinal examination may reveal an embolus, which can confirm the diagnosis. Auscultation for carotid bruits, examination of peripheral pulses, and assessment for temporal artery tenderness are essential. Patients should be questioned about symptoms suggestive of giant cell arteritis, including headache, scalp tenderness, fever, and jaw claudication. A focused neurologic examination is necessary to evaluate for signs of hemispheric stroke, such as contralateral weakness, sensory loss, or aphasia.
Laboratory evaluation includes a complete blood count along with erythrocyte sedimentation rate and C-reactive protein to assess for inflammation, particularly when giant cell arteritis is suspected. Additional studies include serum chemistries, lipid profile, hemoglobin A1C, cardiac enzymes, and electrocardiography. A hypercoagulable workup may be pursued selectively in younger patients or when the history suggests an underlying thrombophilic disorder.
Imaging studies are central to evaluation. CT or MR angiography of the head and neck is preferred to assess carotid and intracranial vasculature, with carotid ultrasound as an alternative when angiography is contraindicated. MRI of the brain with diffusion-weighted imaging is recommended to identify silent or symptomatic infarcts. Transthoracic echocardiography is used to screen for cardiac embolic sources, while transesophageal echocardiography provides greater sensitivity for detecting left atrial appendage thrombi, patent foramen ovale, ventricular mural thrombus, or aortic arch atheroma. Extended cardiac rhythm monitoring is advised when neither carotid disease nor giant cell arteritis explains the presentation.
Management begins with nonpharmacologic therapy, including dietary modification to reduce saturated fats and cholesterol, regular exercise, and cessation of tobacco and illicit drug use. These measures address the underlying vascular risk factors that contribute to embolic disease.
From an acute management standpoint, amaurosis fugax should be treated as a medical emergency, similar to other forms of TIA. Aspirin therapy should be initiated promptly. If giant cell arteritis is suspected, high-dose prednisone must be started immediately, and the patient should be referred urgently for temporal artery biopsy within 48 hours.
Chronic management focuses on secondary stroke prevention. Carotid endarterectomy is recommended for patients with carotid stenosis greater than 50%, and carotid stenting may be considered in patients who are poor surgical candidates. Aggressive management of vascular risk factors—including hypertension, hyperlipidemia with statin therapy, diabetes, and smoking cessation—is essential. Antiplatelet therapy is indicated for atherosclerotic disease or following carotid intervention, while anticoagulation is required when atrial fibrillation is identified as the etiology.
Regarding prognosis, patients with greater than 50% carotid stenosis who do not undergo carotid endarterectomy and present with transient monocular blindness have an estimated 10% risk of stroke within 3 years, compared with approximately 20% risk in those presenting with hemispheric TIA.
Appropriate referral is critical. As with any TIA, patients should undergo emergent inpatient evaluation at a certified stroke center whenever possible. Carotid endarterectomy or stenting should be considered in patients with ipsilateral high-grade stenosis (≥70%), and may also be appropriate for stenosis of 50%–69% or in patients experiencing multiple TIAs despite optimal medical therapy.
Key clinical pearls include recognizing that visualization of cholesterol emboli in retinal arteries on fundoscopy confirms the diagnosis, understanding that transient visual loss has multiple potential causes, and ensuring that amaurosis fugax is managed with the same urgency as other transient ischemic attacks.
- Published on
KembaraXtra-Medicine – Anal Fissure
An anal fissure is a tear in the epithelial lining of the anal canal, extending from the dentate line to the anal verge. Acute anal fissures usually heal with conservative treatment within 6 weeks, while chronic fissures typically need a more aggressive approach and may require surgery. Synonyms include anorectal fissure and anal ulcer. The ICD-10CM codes are K60.0 (acute anal fissure), K60.1 (chronic anal fissure), and K60.2 (anal fissure, unspecified).
An estimated 235,000 new cases occur each year in the United States. Anal fissures can happen at any age but are more common in infants and middle-aged adults, and they occur more often in men than women. Women are more likely than men to have an anterior fissure (10% vs 1%, respectively).
Clinically, separating the buttocks typically reveals a tear in the posterior midline or less often the anterior midline. Acute fissures usually cause sharp burning or tearing pain with bowel movements and may produce bright-red blood on toilet paper, as a streak on stool, or in the toilet water; they look like a fresh laceration. Chronic fissures are more associated with perianal pruritus or irritation, less intense pain or no pain, and intermittent bleeding. They may show a sentinel tag at the caudal aspect, a hypertrophied anal papilla proximally, and raised edges that expose the horizontal fibers of the internal anal sphincter, reflecting chronic infection and fibrosis. Atypical fissures (acute or chronic) are more likely to appear off the midline, may extend proximal to the dentate line, may be unusually wide or deep, and may be multiple, recurring, or nonhealing; they can be associated with an edematous, tender perianal tag and are more often linked to an underlying systemic disease.
Most fissures start after passing a large, hard stool, but they can also result from frequent defecation and diarrhea. Infectious causes include bacterial infections such as tuberculosis, syphilis, gonorrhea, chancroid, and lymphogranuloma venereum, and viral infections such as herpes simplex virus, cytomegalovirus, and HIV. Other causes include inflammatory bowel disease (Crohn disease, ulcerative colitis), trauma (e.g., hemorrhoidectomy, foreign bodies, anal intercourse), and malignancy (carcinoma, lymphoma, Kaposi sarcoma).
Important differential diagnoses include proctalgia fugax, thrombosed hemorrhoid, carcinoma, and anal fistula. Evaluation may include a digital rectal examination performed only after fully lubricating the anus with 2% lidocaine jelly and waiting 5–10 minutes, plus anoscopy and proctosigmoidoscopy to exclude inflammatory or neoplastic disease. A biopsy is recommended if there is doubt about the cause, and studies should be done with adequate anesthesia. Colonoscopy is considered if IBD or malignancy is suspected, and a small-bowel series is occasionally obtained for similar reasons.
Nonpharmacologic management includes sitz baths, a high-fiber diet, and increased oral fluids. Acute treatment includes a bulk-forming agent (e.g., Metamucil) and/or a stool softener, and local anesthetic jelly (though it may worsen pruritus ani). Nitroglycerin ointment 0.4% can be used by applying 1 inch of ointment (≈1.5 mg nitroglycerin) intra-anally every 12 hours for up to 3 weeks; this product (Rectiv) can be expensive, and topical diltiazem (pharmacy-compounded) is also effective and usually cheaper. Suppositories are not recommended. If medical therapy fails after 2 months, surgery is considered.
For chronic fissures, medical therapy may still be offered because it is often better tolerated and avoids the risk of fecal incontinence. Options include topical glyceryl trinitrate, topical calcium channel blockers (e.g., topical nifedipine or topical 2% diltiazem cream), and botulinum toxin A injections into each side of the internal anal sphincter; botulinum toxin can heal chronic fissures in more than 90% of patients, although dosing and best injection site are not fully clear and it can be expensive. The standard, durable surgical treatment is lateral internal anal sphincterotomy, which has >90% long-term healing, is generally durable, and is noted not to compromise long-term fecal continence in the provided text—though it can lead to fecal incontinence and therefore requires careful patient selection.
Disposition is typically outpatient surgery when surgery is needed. Referral is recommended if the fissure does not improve with conservative measures in 4–6 weeks, if the patient prefers surgery for an acute fissure, or if the patient has a chronic fissure. A special consideration is that HIV-positive patients should be referred to clinicians experienced with the infectious and neoplastic conditions that can mimic anal ulcers in this population.
- Published on
KembaraXtra-Medicine – Alzheimer Disease
Dementia is a syndrome characterized by progressive loss of previously acquired cognitive skills, including memory, language, insight, and judgment. Alzheimer disease (AD) is thought to account for the majority of all cases of dementia. The ICD-10CM codes for Alzheimer disease include G30.0 (Alzheimer disease with early onset), G30.1 (Alzheimer disease with late onset), G30.8 (other Alzheimer disease), and G30.9 (Alzheimer disease, unspecified).
The incidence of Alzheimer disease increases markedly with age, with risk doubling every 5 years after age 65. The Chicago Health and Aging Population study demonstrated an average annual incidence of 2.3% among individuals aged 65 years and older, with Black individuals having a significantly increased risk compared with White individuals. In terms of prevalence, approximately 1 in 9 people (10.7%) aged 65 years or older has Alzheimer dementia. In the United States, an estimated 6.5 million people are affected, including 5% of individuals aged 65–74 years, 13.1% of those aged 75–84 years, and 33.2% of those aged 85 years or older. Additionally, 12%–18% of adults over age 60 are believed to have mild cognitive impairment (MCI). Alzheimer disease affects women more frequently than men, with approximately 4 million women and 2.5 million men affected nationwide.
Clinically, Alzheimer disease most often presents insidiously. A spouse or close family member usually first notices progressive memory impairment rather than the patient. Individuals have difficulty learning and retaining new information, managing complex tasks such as finances, and demonstrate impairments in judgment, reasoning, visuospatial abilities, and orientation, often leading to problems such as getting lost or difficulty driving. Behavioral and personality changes, including apathy and mood disturbances, commonly accompany memory loss, and later stages may involve agitation, delusions, or psychosis. Rare atypical variants include early and severe behavioral changes, focal neurologic findings, parkinsonism, hallucinations, frequent falls, or onset of symptoms at or before 65 years of age.
The diagnosis of Alzheimer disease has evolved with the development of biomarkers that demonstrate Alzheimer pathology in vivo, particularly amyloid beta deposition and pathologic tau accumulation. The National Institute on Aging–Alzheimer’s Association (NIA-AA) criteria, initially published in 2011 and revised in 2018, conceptualize Alzheimer disease as a biologic process rather than solely a clinical syndrome. These criteria define three stages: preclinical Alzheimer disease (biologic evidence without symptoms), MCI due to Alzheimer disease (mild memory impairment without functional decline but with biomarker evidence), and dementia due to Alzheimer disease (cognitive decline with functional impairment and biomarker confirmation). The 2018 framework further introduced the ATN system, defining disease by amyloid (A), tau pathology (T), and neurodegeneration (N). Although biomarkers are not yet routinely used in general clinical practice, they are integral to research and clinical trials.
In routine clinical settings, Alzheimer disease is typically diagnosed using clinical history, neurologic examination, and established criteria such as DSM-5 or NINCDS-ADRDA. Core features include progressive memory loss plus at least one additional cognitive deficit (aphasia, apraxia, agnosia, or executive dysfunction), decline in social or occupational functioning, insidious onset with gradual progression, objective documentation of cognitive loss, and exclusion of alternative causes. Red flags suggesting an alternative diagnosis include age younger than 65 years, fluctuating consciousness, rapid progression over months, prominent early behavioral changes, or focal neurologic findings such as gait disturbance, lateralized weakness, myoclonus, or parkinsonism.
The differential diagnosis of Alzheimer disease is broad and includes other neurodegenerative dementias such as frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson disease dementia, corticobasal syndrome, progressive supranuclear palsy, limbic-predominant age-related TDP-43 encephalopathy, and primary age-related tauopathy. Nondegenerative conditions include vascular cognitive impairment, depression (pseudodementia), subjective memory complaints, brain tumors, chronic subdural hematoma, infections such as HIV or neurosyphilis, toxic or metabolic encephalopathies, and organ failure–related cognitive impairment.
Evaluation begins with a comprehensive history and physical examination, including careful medication review to identify agents that impair cognition, such as anticholinergics, benzodiazepines, opioids, barbiturates, and neuroleptics. Screening for depression is essential, as it may mimic or coexist with dementia. Cognitive screening tools such as the Mini-Mental State Examination, Mini-Cog, and Montreal Cognitive Assessment are commonly used, while formal neuropsychologic testing is reserved for atypical cases or diagnostic uncertainty. In Alzheimer disease, episodic memory deficits typically appear early, whereas attention is often preserved until later stages.
Laboratory evaluation usually includes complete blood count, serum electrolytes, glucose, renal and liver function tests, thyroid function tests, and vitamin B12 levels, with additional testing guided by clinical context. Neuroimaging, preferably MRI, is used to exclude alternative diagnoses and assess characteristic patterns of neurodegeneration, such as hippocampal atrophy. Amyloid and tau PET imaging may support diagnosis in selected cases but are not diagnostic on their own.
Management of Alzheimer disease incorporates both nonpharmacologic and pharmacologic strategies. Nonpharmacologic care focuses on patient safety, caregiver education, behavioral interventions, and cognitive stimulation. Addressing driving safety, wandering, medication management, and household hazards is essential. Behavioral symptoms such as agitation, repetitive questioning, and social withdrawal often respond to structured routines and environmental modifications. A person-centered, interdisciplinary approach tailored to disease stage improves quality of life for both patients and caregivers.
Pharmacologic treatment is primarily symptomatic. Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are approved for mild to moderate Alzheimer disease, with donepezil also approved for severe disease. These agents provide modest cognitive and functional benefits but may cause gastrointestinal effects, bradycardia, and sleep disturbances. Memantine, an NMDA receptor antagonist, is approved for moderate to severe Alzheimer disease. Newer anti-amyloid monoclonal antibodies, such as aducanumab and lecanemab, target amyloid pathology and may modestly slow cognitive decline in early disease but require careful patient selection and monitoring due to safety concerns.
Patients with atypical presentations or complex management needs should be referred to specialists with expertise in dementia care. Ongoing caregiver education and support are critical, as they reduce caregiver burden, delay institutionalization, and improve patient outcomes. Prevention strategies emphasize physical activity, cardiovascular risk factor control, cognitive engagement, healthy diet patterns, and avoidance of tobacco and excessive alcohol use.
